Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age

Abstract

Candesartan cilexetil dose-dependently decreases blood pressure and albuminuria in hypertensive infants and is generally well tolerated.

2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents

“…The different classes of antihypertensive agents are comparable with respect to their BP-lowering efficacy in children with CKD (228,229), but most of the available clinical evidence has been obtained with drugs blocking the renin-angiotensin system (RAS) (25,228,230). They have a powerful, dosedependent antiproteinuric action in pediatric nephropathies (231). RAS inhibitors in general have a favourable side effect profile; however, a few fatalities have been documented in infants with acute intravascular volume depletion while receiving angiotensin receptor blockers (231,232).…”

“…They have a powerful, dosedependent antiproteinuric action in pediatric nephropathies (231). RAS inhibitors in general have a favourable side effect profile; however, a few fatalities have been documented in infants with acute intravascular volume depletion while receiving angiotensin receptor blockers (231,232). It is recommended to use RAS blocking agents as first choice with 40 appropriate risk counselling in all proteinuric patients with CKD.…”

Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age

“…However, very few reported controlled clinical trials have evaluated the use of antihypertensive drugs in children aged less than 6 years [7,8].…”

Pharmacologic Management of Pediatric Hypertension

“…They should be avoided in patients with acute kidney injury. Adverse effects reported in trials for patients less than 6 years of age have led to some safety concerns [42,43], though they are used with some regularity in this age group. ARBs do not inhibit the breakdown of kinins and therefore cause cough less frequently than ACE inhibitors.…”